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INTRODUCTION: CANNABIS CONTINUES TO AFFECT MENTAL HEALTH. 
ITS ABUSE IS ON RISE GLOBALLY. IN CANADA A RISE BY 30% IN 
LAST TEN YEARS HAS BEEN OBSERVED IN HIGH SCHOOL STUDENTS. 
INTERRELATIONSHIP OF CANNABIS WITH PSYCHOSIS
AND SCHIZOPHRENIA IS A COMPLEX ONE. CANNABIS IS HIGHLY 
COMORBID WITH PSYCHOSIS, & RELATED TO FUNCTIONAL 
DISABILITY AND OUTCOME. IT POSES SEVERAL CHALLENGES IN
UNDERSTANDING CAUSAL RELATIONSHIP FOR COMORBIDITY, 
UNDERLYING NEUROCHEMICAL BASIS AND SPECIFICS OF SERVICE 
DEVELOPMENT. PREVALENCE OF CANNABIS VARIES FROM 20 TO
50% EARLY PSYCHOSIS. OBJECTIVE OF THIS PAPER IS TO REVIEW 
AVAILABLE LITERATURE TO IDENTIFY CHALLENGES FOR NEWER 
TARGETS OF RESEARCH AND PREVENTIVE MEASURES.
METHOD: RECENT LITERATURE FROM ELECTRONIC DATA BASE 
SEARCH IDENTIFIES ROLE AND RELATIONSHIP OF CANNABIS AND 
PSYCHOSIS.
RESULTS. CANNABIS IS A RISK FACTOR FOR BOTH PSYCHOSIS AND 
SCHIZOPHRENIA & APPEARS TO HAVE CAUSAL RELATIONSHIP FOR 
EARLY AND LATERAGE PSYCHOSIS. MOOD SYMPTOMS ARE ALSO 
SIGNIFICANT BUT LESS RECOGNIZED.
UNDERSTANDINGS OF THE PROCESS AND CAUSES HAVE 
SIGNIFICANTLY ADVANCED WITH DISCOVERY OF CANNABINOID 
RECEPTORS AND ENDOGENOUS CANNABINOIDS. IT IS CLEAR THAT 
CANNABIS INCREASES BRAIN VULNERABILITY, CAUSES POORER
OUTCOME AND MORE SIDE EFFECTS. CANNABIS CAUSES COGNITIVE 
DYSFUNCTION THAT PERHAPS WORKS AS A COMMON 
DENOMINATOR FOR THE RISK-VULNERABILITY. IT APPEARS TO HAVE
INDEPENDENT GENETIC COMPONENT RELATED TO DISRUPTION IN 
NEUROTRANSMISSION AFFECTING NEURONAL PLASTICITY. MUCH 
LESS ATTENTION HAS BEEN PAID IN DEVELOPING SERVICES 
TARGETED TOWARDS HARM REDUCTION AND DEVELOPING
THERAPEUTICS.
CONCLUSION. CANNABIS IS POTENTIAL RISK FACTOR FOR POORER 
OUTCOME IN PSYCHOSIS. NEW BIOLOGICAL AND SOCIAL SERVICE 
INITIATIVES WILL ADD VALUE TO EARLY PSYCHOSIS PROGRAMS.
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1. EVER USE OF CANNABIS IN UK IS ESTIMATED 40% WITH INCREASED RISK OF 1.4 TIMES PROJECTS 14% 
OF PSYCHOTIC OUTCOME IN YOUNG ADULTS IN UK 
2. PROJECTED TREND IN SCHIZOPHRENIA HAS NOT PARALLELED TRENDS IN CANNABIS USE- MISMATCH.
WHAT DO WE KNOW WITH LIMITED EVIDENCE?
THE BRAIN CHANGES SEEN BY IMAGING
INFLUENCE ON BRAIN DEVELOPMENT DURING ADOLESCENCE 
NATURE OF MOST TOXIC METABOLITE WHICH IS PSYCHOSIS - GENIC.
ROLE OF CB RECEPTORS IN SCHIZOPHRENIA AND PSYCHOSIS
THE PATHOGENESIS OF RISK.
THE ‘CANNABIS PHENOTYPE OF PSYCHOSIS’
VALIDITY OF DIAGNOSIS : ‘ CANNABIS-INDUCED- PSYCHOSIS VS. CANNABIS-TOXIC-
PSYCHOTIC STATE
THERE ARE SEVERAL HYPOTHESES FOR WHY MENTAL ILLNESS AND SUBSTANCE 
ABUSE CO-OCCUR
 SUBSTANCE ABUSE IS ONE OF THE CAUSES FOR SEVERITY OF FUNCTIONAL 
DEFICIT IN SCHIZOPHRENIA
1. A  SIMILAR NEUROBIOLOGICAL BASIS TO BOTH;
2. SUBSTANCE USE -- ALLEVIATE SOME OF THE SYMPTOMS OR THE SIDE EFFECTS  
3. MAY PRECIPITATE MENTAL ILLNESSES OR LEAD TO BIOLOGICAL CHANGES THAT 
AVAILABLE RESOURCES ON THE KEY WORD  ‘PSYCHOSIS’ &  ‘CANNABIS’ WAS 
SEARCHED IN ELECTRONIC RESOURCE, AND KEY FINDINGS WERE SUMMARIZED.
CANNABIS IS A MAJOR PUBLIC HEALTH PROBLEM, HAVING SIGNIFICANT 
MENTAL HEALTH IMPACT. IT IS ONE OF THE MAIN COMORBIDITY IN PSYCHOSIS, 
THOUGH FOUND WITH VARYING DEGREE IN DIFFERENT CULTURES E.G. VERY LOW 
IN INDIAN STUDIES, 40-50% IN EUROPEAN COUNTRIES, 650-6-% IN CANADIAN 
POPULATION & 60-70% IN USA POPULATIONS.. IT HAS BEEN FOUND BEYOND 
DOUBT TO BE ONE OF THE MAJOR RISK FACTOR FOR DEVELOPING PSYCHOSIS, 
PARTICULARLY USING CANNABIS IN THE AGE OF 13 TO 15 YEARS. COGNITIVE 
DYSFUNCTION APPEARS TO BE A COMMON DENOMINATOR IN PSYCHOSIS S 
WELL AS CANNABIS ABUSE. EVIDENCE FOR INVOLVEMENT OF CANNABIS IN 
DEVELOPING PSYCHOSIS HAS GATHERED FROM MULTIPLE SOURCES : 
EPIDEMIOLOGICAL, META ANALYSIS, NEUROCHEMICAL, RECEPTOR, IMAGING 
AND GENETIC STUDIES. IT IS SUGGESTED THAT THERE IS A POSSIBILITY OF 
CANNABIS UNMASKING THE VULNERABILITY AND CHANGING THE RESILIENCE IN 
INDIVIDUALS SUSCEPTIBLE TO SCHIZOPHRENIA. HOWEVER WHILE IN CLINICAL 
PRACTICE THIS HAS NOT RECEIVED SUFFICIENT ATTENTION , AND IN RESEARCH 
THERE ARE ‘MISSING LINKS’ IN ‘PSYCHOSIS-RELATED-TO-CANNABIS’. THE 
PAPER DISCUSSES SOME OF THE IMPORTANT AREAS OF CLINICALLY RELEVANT 
RESEARCH REQUIRING ATTENTION IN INTEREST OF ENHANCING QUALITY OF 
SERVICE AND SAFETY OF PATIENTS. CANNABIS  HAS A HISTORY OF 4000 
YEARS. IT IS WORLD’S MOST ABUSED ILLICIT DRUG. THERE ARE 165 MILLION 
ABUSERS IN 172 COUNTRIES. IT HAS 64 METABOLITES AND MOST ACTIVE ONE 
IS TRIHYDROCANNABIDOL (THC).A RECENT STUDY IN CANADA SHOWS THAT 
60% BOYS AND 50 GIRLS IN HIGH SCHOOL USE MARIJUANA (2002) 
REGISTERING 40% INCREASE SINCE 1990, IN 12 YEARS.    
A SYSTEMATIC HISTORICAL DEVELOPMENT IS WORTH A LOOK:  
-1200 BC  INDUS VALLEY- FIVE SACRED PLANTS - 1894 NO EVIDENCE OF 
MENTAL OR MORAL  INJURIES  1928  RECREATIONAL USE BANNED IN UK    
1942  REMOVED FROM AMERICAN PHARMACOPEIA   1961 60 NATIONS 
SIGNED  ‘END CANNABIS IN 25 YEARS  1985 THC ISOLATED  1970 CLEAR 
EVIDENCE OF PSYCHOLOGICAL EFFECT 1987 FIRST EVIDENCE OF LINK WITH 
SCHIZOPHRENIA 1988 CB RECEPTORS DISCOVERED BY HEWLETT & DEVANE 
1992 FIRST ENDOCANNABINOID DISCOVERED 2000 AGONIST SHOWN TO 
REDUCE PLASTICITY 2002 EFFECT ON LONG TERM PLASTICITY 2005 
CANNABIS BASED MEDICINE FOR MS IN 1970 IN  CANADA 
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